Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep Torrent

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Orphanet Journal of Rare Diseases|November 17, 2018
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertaintiesCaridad Pontes, Juan Manuel Fontanet, Roser Vives, et al.
Orphanet Journal of Rare Diseases|March 12, 2017
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)Lieven Annemans, Ségolène Aymé, Yann Le Cam, et al.
Applied Health Economics and Health Policy|November 8, 2019
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of OlaratumabCaridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Orphanet Journal of Rare Diseases|November 17, 2018
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertaintiesCaridad Pontes, Juan Manuel Fontanet, Roser Vives, et al.
Orphanet Journal of Rare Diseases|March 12, 2017
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)Lieven Annemans, Ségolène Aymé, Yann Le Cam, et al.
Applied Health Economics and Health Policy|November 8, 2019
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of OlaratumabCaridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 2